Isotechnika Pharma signs pact with US FDA on SPA for its lead candidate ... pharmabiz.com Both phase III trials will aim to demonstrate non-inferiority in an efficacy endpoint, primarily driven by biopsy proven acute rejection, or BPAR, compared to tacrolimus. A key secondary endpoint will be the incidence of New Onset Diabetes After ... |
